Enterprise Value
2.959M
Cash
10.74M
Avg Qtr Burn
-2.479M
Short % of Float
0.96%
Insider Ownership
16.38%
Institutional Own.
4.88%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PCS12852 Details Opioid induced constipation, Post-op GI Dysfunction | Phase 2b Update | |
PCS6422 w/ capecitabine (NGC-Capecitabine) Details Solid tumor/s, Colorectal cancer , Cancer, Metastatic breast cancer | Phase 1b Update | |
PCS499 Details Ulcerative Necrobiosis Lipoidica | Failed Discontinued |